CN112121171A - 神经活性化合物及其使用方法 - Google Patents

神经活性化合物及其使用方法 Download PDF

Info

Publication number
CN112121171A
CN112121171A CN202011059273.5A CN202011059273A CN112121171A CN 112121171 A CN112121171 A CN 112121171A CN 202011059273 A CN202011059273 A CN 202011059273A CN 112121171 A CN112121171 A CN 112121171A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
alkyl
group
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202011059273.5A
Other languages
English (en)
Chinese (zh)
Inventor
M.C.夸克
J.J.多尔蒂
G.马丁内斯博泰拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics Inc
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of CN112121171A publication Critical patent/CN112121171A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN202011059273.5A 2014-10-07 2015-10-07 神经活性化合物及其使用方法 Pending CN112121171A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462060932P 2014-10-07 2014-10-07
US62/060,932 2014-10-07
CN201580063540.7A CN107405352A (zh) 2014-10-07 2015-10-07 神经活性化合物及其使用方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580063540.7A Division CN107405352A (zh) 2014-10-07 2015-10-07 神经活性化合物及其使用方法

Publications (1)

Publication Number Publication Date
CN112121171A true CN112121171A (zh) 2020-12-25

Family

ID=55653736

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011059273.5A Pending CN112121171A (zh) 2014-10-07 2015-10-07 神经活性化合物及其使用方法
CN201580063540.7A Pending CN107405352A (zh) 2014-10-07 2015-10-07 神经活性化合物及其使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580063540.7A Pending CN107405352A (zh) 2014-10-07 2015-10-07 神经活性化合物及其使用方法

Country Status (17)

Country Link
US (2) US20170304321A1 (enExample)
EP (1) EP3204011A4 (enExample)
JP (3) JP2017530982A (enExample)
KR (1) KR20170065637A (enExample)
CN (2) CN112121171A (enExample)
AU (2) AU2015330906A1 (enExample)
BR (1) BR112017007053A2 (enExample)
CA (1) CA2963938C (enExample)
IL (2) IL292465B2 (enExample)
MX (2) MX388694B (enExample)
MY (1) MY202135A (enExample)
PE (1) PE20170907A1 (enExample)
PH (1) PH12017500639A1 (enExample)
RU (1) RU2764702C2 (enExample)
SG (2) SG10202011773UA (enExample)
WO (1) WO2016057713A1 (enExample)
ZA (1) ZA201702545B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI2753632T3 (fi) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
KR102280614B1 (ko) 2013-03-15 2021-07-21 글로벌 블러드 테라퓨틱스, 인크. 헤모글로빈 조정을 위한 화합물 및 이의 용도
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
AU2014369916A1 (en) 2013-12-24 2016-06-16 Durect Corporation Uses of oxygenated cholesterol sulfates (OCS)
ES2970222T3 (es) 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
MX390271B (es) 2015-07-06 2025-03-20 Sage Therapeutics Inc Oxiesteroles y metodos de uso de los mismos
FI3828194T3 (fi) 2015-07-06 2025-07-17 Sage Therapeutics Inc Oxysteroleita ja menetelmiä niiden käyttämiseksi
MA42409A (fr) * 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
LT3481846T (lt) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
PT3494125T (pt) 2016-08-02 2022-07-07 Durect Corp Composições compreendendo 5-colesten-3, 25-diol, 3-sulfato (25hc3s), ou seu sal farmaceuticamente aceitável, e, pelo menos, um oligossacárido cíclico
JP7149266B2 (ja) 2016-09-30 2022-10-06 セージ セラピューティクス， インコーポレイテッド Ｃ７置換オキシステロールおよびｎｍｄａモジュレーターとしての方法
MA46566A (fr) 2016-10-18 2019-08-28 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation
IL293231B2 (en) 2016-10-18 2025-10-01 Sage Therapeutics Inc Oxysterols and methods of use thereof
EP3335730A1 (en) * 2016-12-15 2018-06-20 Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) Compounds for treating x-linked adrenoleukodystrophy
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604011B2 (en) * 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2014160441A1 (en) * 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB0712494D0 (en) * 2007-06-27 2007-08-08 Isis Innovation Substrate reduction therapy
WO2009059961A2 (en) * 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
BRPI0912362A2 (pt) * 2008-05-09 2015-10-06 Univ Emory antagonista do receptor nmda para o tratamento de transtornos neuropsiquiátricos
WO2010065709A2 (en) * 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
FI2753632T3 (fi) 2011-09-08 2023-08-02 Sage Therapeutics Inc Neuroaktiivisia steroideja, koostumuksia ja niiden käyttöjä
EP2841067A4 (en) * 2012-04-25 2016-04-13 Univ California MEDICINAL SCREENING PLATFORM FOR THE RETT SYNDROME
WO2014025942A1 (en) * 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
CA2898863A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
RS67266B1 (sr) 2013-03-13 2025-10-31 Sage Therapeutics Inc Neuroaktivni steroidi i postupci za njihovu upotrebu
ES2970222T3 (es) * 2014-06-18 2024-05-27 Sage Therapeutics Inc Oxiesteroles y procedimientos de uso de los mismos
WO2016007762A1 (en) * 2014-07-09 2016-01-14 Duke University Compositions and methods for the repair of myelin
MA42409A (fr) * 2015-07-06 2018-05-16 Sage Therapeutics Inc Oxystérols et leurs procédés d'utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604011B2 (en) * 2004-09-27 2013-12-10 The Regents Of The University Of California Therapy for treatment of chronic degenerative brain diseases and nervous system injury
WO2014160441A1 (en) * 2013-03-13 2014-10-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ELAINE TIERNEY等: "Abnormalities of Cholesterol Metabolism in Autism Spectrum Disorders", 《AMERICAN JOURNAL OF MEDICAL GENETICS PART B (NEUROPSYCHIATRIC GENETICS)》 *

Also Published As

Publication number Publication date
IL292465B1 (en) 2025-02-01
IL251505B (en) 2022-05-01
KR20170065637A (ko) 2017-06-13
NZ730862A (en) 2024-01-26
IL251505A0 (en) 2017-05-29
RU2017115849A3 (enExample) 2019-05-15
RU2764702C2 (ru) 2022-01-19
MX2017004684A (es) 2017-06-30
MX2021011939A (es) 2021-11-03
JP2022033285A (ja) 2022-02-28
JP2020196759A (ja) 2020-12-10
US20170304321A1 (en) 2017-10-26
MX388694B (es) 2025-03-20
RU2017115849A (ru) 2018-11-13
BR112017007053A2 (pt) 2018-06-19
CA2963938A1 (en) 2016-04-14
PH12017500639A1 (en) 2017-09-25
JP2017530982A (ja) 2017-10-19
US20230218638A1 (en) 2023-07-13
AU2021200721B2 (en) 2023-06-01
CN107405352A (zh) 2017-11-28
ZA201702545B (en) 2019-06-26
WO2016057713A1 (en) 2016-04-14
EP3204011A1 (en) 2017-08-16
IL292465A (en) 2022-06-01
PE20170907A1 (es) 2017-07-12
CA2963938C (en) 2023-10-24
AU2015330906A1 (en) 2017-04-27
SG10202011773UA (en) 2021-01-28
SG11201702799UA (en) 2017-05-30
AU2021200721A1 (en) 2021-03-04
IL292465B2 (en) 2025-06-01
MY202135A (en) 2024-04-05
EP3204011A4 (en) 2018-06-20

Similar Documents

Publication Publication Date Title
AU2021200721B2 (en) Neuroactive compounds and methods of use thereof
JP7602513B2 (ja) オキシステロールおよびそれらの使用の方法
JP7602512B2 (ja) オキシステロールおよびそれらの使用の方法
JP7715692B2 (ja) 神経刺激性ステロイドおよびその使用方法
JP7693755B2 (ja) オキシステロールおよびその使用方法
JP6628745B2 (ja) オキシステロールおよびその使用方法
EP3674298A1 (de) Substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
WO2017193046A1 (en) Oxysterols and methods of use thereof
RU2850468C2 (ru) Оксистеролы и способы их применения
RU2808166C2 (ru) Нейроактивные стероиды и способы их применения

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20201225

RJ01 Rejection of invention patent application after publication